AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.0800
+0.0400 (+0.99%)
At close: 4:00PM EST

4.08 0.00 (0.00%)
After hours: 4:29PM EST

Stock chart is not supported by your current browser
Previous Close4.0400
Open4.0300
Bid4.03 x 1000
Ask4.12 x 2900
Day's Range4.0215 - 4.1300
52 Week Range3.1400 - 31.3500
Volume1,548,169
Avg. Volume3,138,583
Market Cap512.007M
Beta (3Y Monthly)3.30
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateFeb 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est8.00
Trade prices are not sourced from all markets
  • Business Wire1 hour ago

    EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Akorn, Inc. – AKRX

    Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Akorn, Inc. (AKRX) from August 1, 2018 through January 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Akorn investors under the federal securities laws. To join the Akorn class action, go to https://www.rosenlegal.com/cases-1497.html or call Phillip Kim, Esq.

  • ACCESSWIRE2 hours ago

    Akorn, Inc. (AKRX) Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation

    NEW YORK, NY / ACCESSWIRE / February 21, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akorn Inc.("Akorn" or the "Company") ...

  • GlobeNewswire23 hours ago

    Akorn Comments on Fresenius’ Proposed Amended Claims

    Akorn, Inc. (AKRX) today announced that it strongly contests Fresenius’ proposed amended claims filed earlier today. Akorn believes these claims are meritless and overreaching. Akorn denies the allegations and will vigorously defend itself in this litigation, while continuing to focus on advancing its pipeline, strengthening its business and developing a strategic plan for improving financial performance and long-term shareholder value.

  • GlobeNewswireyesterday

    AKRX INVESTOR LOSSES ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Akorn, Inc.; Akorn Investors are Encouraged to Contact the Firm – AKRX

    NEW YORK, Feb. 20, 2019 -- Rosen Law Firm, a global investor rights law firm, announces it is continuing to investigate potential securities claims on behalf of shareholders of.

  • Moody's6 days ago

    Akorn, Inc. -- Moody's announces completion of a periodic review of ratings of Akorn, Inc.

    Announcement: Moody's announces completion of a periodic review of ratings of Akorn, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Akorn, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • GlobeNewswire6 days ago

    EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Akorn, Inc. – AKRX

    NEW YORK, Feb. 15, 2019 -- Rosen Law Firm, a global investor rights law firm, announces it is continuing to investigate potential securities claims on behalf of shareholders of.

  • GlobeNewswire10 days ago

    Akorn to Report Fourth Quarter and Full Year 2018 Results

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, February 28, 2019 outlining the fourth quarter and full year 2018 results. In addition, the Company has scheduled a conference call at 10:00 a.m. ET on the same day to discuss its fourth quarter and full year 2018 financial results. To access the live webcast, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    Akorn Inc NASDAQ/NGS:AKRXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for AKRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AKRX totaled $6.68 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire20 days ago

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akorn, Inc. (“Akorn” or “the Company”) (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Akorn disclosed that it received an FDA warning letter on January 9, 2019, based on an inspection of the Company’s manufacturing facility located in Decatur, Illinois. The inspection and subsequent warning letter revealed that Akorn had failed to follow federal regulations on drug manufacturing, despite having communicated the opposite to shareholders.

  • Business Wire21 days ago

    INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akorn, Inc. (“Akorn” or “the Company”) (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Akorn disclosed that it received an FDA warning letter on January 9, 2019, based on an inspection of the Company’s manufacturing facility located in Decatur, Illinois.

  • GlobeNewswire21 days ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akorn, Inc. (AKRX) 

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akorn Inc. (“Akorn” or the “Company”) (AKRX).  Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/akrx. The investigation concerns whether Akorn and certain of its officers and/or directors have violated federal securities laws. On January 9, 2019, Akorn revealed that it had received a warning letter from the U.S. Food and Drug Administration after an inspection of Akorn’s Decatur, Illinois manufacturing facility.

  • Business Wire22 days ago

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akorn, Inc. (“Akorn” or “the Company”) (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Akorn disclosed that it received an FDA warning letter on January 9, 2019, based on an inspection of the Company’s manufacturing facility located in Decatur, Illinois.

  • Business Wire22 days ago

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Akorn, Inc. – AKRX

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Akorn, Inc. resulting from allegations that Akorn may have issued materially misleading business information to the investing public.

  • GlobeNewswire22 days ago

    Akorn, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

    BOSTON, Jan. 30, 2019 -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Akorn, Inc..

  • GlobeNewswire24 days ago

    Akorn Announces New Executive and Board Appointments

    Akorn, Inc. (AKRX), today announced that it has appointed a new executive team member and two new board members. Christopher C. Young joins Akorn as Executive Vice President, Global Operations reporting to Douglas Boothe, President & Chief Executive Officer.  Young brings twenty-five years of pharmaceutical experience to Akorn having most recently been the Executive Vice President of Global Operations for Alvogen, Inc.  Prior to Alvogen, Young was Vice President of Operations in the United States and India for Actavis.  He brings to Akorn a strong history of U.S. and global expertise in operations, supply chain, integration, remediation and operational excellence.  His leadership and skills are well matched for the current challenges that the Company is facing with increased competition and a complex regulatory landscape.

  • Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
    Zackslast month

    Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility

    Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.

  • PR Newswirelast month

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akorn, Inc. - AKRX

    NEW YORK, Jan. 9, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Akorn, Inc. ("Akorn" or the "Company") (NASDAQ:  AKRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Akorn and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On January 9, 2019, Akorn disclosed that it received a warning letter from the U.S. Food and Drug Administration, after the company's Decatur, Illinois manufacturing facility was inspected by the regulatory authority in April and May 2018.

  • Moody'slast month

    Akorn, Inc. -- Moody's says receipt of FDA Warning Letter on Akorn's Decatur facility is credit negative

    Moody's Investors Service commented that Akorn, Inc.'s ("Akorn") receipt of a warning letter from the US Food & Drug Administration ("FDA") related to its Decatur manufacturing facility is credit negative. The warning letter is credit negative as Akorn will be unable to have drugs approved out of that facility until the compliance issues are addressed.

  • Reuterslast month

    Akorn gets FDA warning letter for Illinois plant, shares drop

    Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year. The warning letter, dated Friday, lists violations related to the agency's current good manufacturing practice regulations, which include poor aseptic behavior, as well as those related to environmental and personnel monitoring. The FDA said the company's response to its Form 483, which lists observations from the inspection in April and May, was inadequate.

  • Benzingalast month

    Akorn Slides After Reporting FDA Warning Letter On Illinois Facility

    Akorn said Wednesday ahead of the market open that the FDA sent a Jan. 4 warning letter tied to inspections of its Decatur, Illinois manufacturing facility that were conducted in April and May 2018. The FDA took exception to the company's failure to follow written procedures designed to prevent microbiological contamination of drug products, as well as a lack of control systems to prevent contamination and a written testing program to assess stability characteristics of drugs.

  • Reuterslast month

    Akorn gets warning letter from the FDA

    Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration, after the company's Decatur, Illinois manufacturing facility was inspected by the regulatory authority ...

  • MarketWatchlast month

    Akorn receives 'warning letter' from FDA related to a manufacturing facility

    Akorn Inc. said Wednesday that it received a warning letter from the Food and Drug Administration, related to an inspection of the generic drug maker's Decatur, Illinois manufacturing facility. The stock was halted for news, and was inactive prior to the halt. The FDA had investigated the facility in April and May 2018. The company said it will respond to the FDA letter, dated Jan. 4, within 15 working days. "Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter," Akorn said in a statement. The stock has tumbled 39% over the past three months, while the S&P 500 has lost 10.6%.

  • GlobeNewswirelast month

    Akorn Receives FDA Warning Letter

    Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter.  The Company will respond to the FDA letter within the required 15 working days. The Company has full confidence in the quality of the products manufactured at the Decatur facility and expects to continue production at the plant.